	US 12,188,056 B2
	Sialyltransferases for in vivo synthesis of 3′SL
Manos Papadakis, Hørsholm (DK)
Assigned to DSM IP Assets B.V., Heerlan (NL)
Filed by DSM IP Assets B.V., Heerlan (NL)
Filed on Mar. 1, 2023, as Appl. No. 18/177,070.
Claims priority of application No. PA202270077 (DK), filed on Mar. 2, 2022.
Prior Publication US 2024/0141307 A1, May 2, 2024
Int. Cl. C12N 9/10 (2006.01); C07K 14/24 (2006.01); C12P 19/04 (2006.01); C12P 19/18 (2006.01)

CPC C12N 9/1081 (2013.01) [C07K 14/24 (2013.01); C12P 19/04 (2013.01); C12P 19/18 (2013.01); C12Y 204/99004 (2013.01)]

20 Claims

1. A genetically modified cell comprising a heterologous recombinant nucleic acid sequence encoding an enzyme with α-2,3-sialyltransferase activity, wherein the enzyme is Poral with at least 80% identity to the amino acid sequence set forth in SEQ ID NO: 3, and wherein said cell produces a sialylated human milk oligosaccharide (HMO).